In Flemingsberg, we cure diseases that were previously considered incurable

Earlier this year we hosted the most meaningful ATMP event of the spring, in collaboration with Miltenyi Biotec and the Karolinska ATMP Center, Karolinska University Hospital and Karolinska Institutet. We gathered over 120 participants, all sharing a vision of creating momentum to accelerate access to ATMPs in the Nordics.

”It’s fantastic, it’s a great opportunity to learn more about what’s going on at Karolinska and for the whole ATMP environment. From the Pre GMP to the manufacturing, to then the clinical trials that they offer here, and I think that’s one of the things that are really unique about the whole Flemingsberg ATMP ecosystem” – Jonathan Clarke, Development Manager at SmartCella.

During the event we launched ATMP Flemingsberg, a platform that encapsulates all the expertise within ATMP in Flemingsberg, from research to clinical implementation.

”We have everything in Flemingsberg and you can see that because they come here from Uppsala and other parts of the world to manufacture their products and do their treatments here” – Ewa Ellis, ATMP coordinator at Karolinska University Hospital.

The seminar shed light on Pre-GMP and GMP, as well as how to advance one’s process to the next level and how Vecura can assist in scaling up. Additionally, Stefan Mielke, an expert in the field, discussed equal access and emphasized the importance of collaborative efforts to make therapies more accessible to patients. Di Yu from Elicera Therapeutics also shared their journey, which began at Vecura in Flemingsberg.

“Clinical trials are very important because they bring innovation to our patients. For those of you who don’t know what CAR-T cells are, they are like glasses for T-cells, so that they can see tumor cells.” – Stephan Mielke, Professor and Scientific Director of the Cancer Center.

Watch our film below, summarizing our successful event. Together, we can accelerate access to ATMPs in the Nordics.

Visit atmpflemingsberg.se

*ATMP (Advanced Therapy Medicinal Products) också kallade Avancerade terapiläkemedel är baserade på celler, vävnader eller gener och delas in i tre huvudkategorier: somatiska cellterapier, genterapier och vävnadstekniska produkter.

Stockholm innovation hubs build knowledge and attractiveness

Innovation hubs such as Flemingsberg Science make it easier to attract the knowledge and competences needed for the development of the sustainable city of the future. “The ability of hubs to rapidly identify needs and trends is crucial for the development of the Stockholm region. Flemingsberg Science strengthens the local ecosystem and contributes to businesses being able to conduct research, and develop and grow in the region, especially in life sciences,” says Anton Västberg, Development Director, Region Stockholm.

From Science Week: Innovative arenas create collaboration for the city of the future

See the panel discussion on how innovative neutral arenas are central to the development of the smart and knowledge-intensive city. Flemingsberg Science CEO Johnny Högberg participates together with a panel consisting of Sophia Sundberg, CEO, Barkaby Science, Peter Dobers, Professor of Business Administration with a focus on sustainable development and collaboration, Södertörn University, Johan Zachrisson, Business Development Manager, Fabege and Anton Västberg, Development Director, Region Stockholm.

Test your business idea: Flemingsberg Science Award Startup open for applications

STARTUP is a competition for startups with a clear connection to Flemingsberg, either as students, residents or otherwise active in the area.All ideas are welcome to participate in STARTUP as long as you compete with your own idea and the turnover and external equity is below SEK 1,000,000 at the time you submit to the competition. After that, we of course welcome you to continue working with the business idea, sales and any investments.

Previous 434445 Next